Lymphoedema in Lentigo Maligna patients treated with imiquimod, a long term adverse effect

Abstract

Lentigo Maligna (LM) is a potential precursor lesion of Lentigo Maligna Melanoma (LMM). It is treated to prevent progression to LMM. A recent epidemiological study reports a progression rate of 2.0-2.6% over a course of 25 years¹. The gold standard of treatment is surgical excision with 5 mm margin². Topical application of imiquimod cream is an off-label alternative.

This article is protected by copyright. All rights reserved.